gefitinib has been researched along with protac-3 in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (protac-3) | Trials (protac-3) | Recent Studies (post-2010) (protac-3) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 6 | 0 | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Cheng, M; Han, X; Jin, J; Liu, J; Lu, K; Meng, F; Wang, L; Xie, L; Xiong, Y; Yu, X | 1 |
| Cheng, M; Jin, J; Liu, J; Lu, K; Shen, Y; Xiong, Y; Yu, X; Zhong, Y | 1 |
2 other study(ies) available for gefitinib and protac-3
| Article | Year |
|---|---|
Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Discovery; ErbB Receptors; Gefitinib; Humans; Male; Mice; Mutation; Protein Kinase Inhibitors; Proteolysis; Signal Transduction; Ubiquitin-Protein Ligases; Von Hippel-Lindau Tumor Suppressor Protein | 2020 |
Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras.
Topics: EGF Family of Proteins; ErbB Receptors; Humans; Phosphatidylinositol 3-Kinases; Proteolysis; Ubiquitin-Protein Ligases | 2022 |